Does DAROLUTAMIDE Cause Myelosuppression? 44 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 44 reports of Myelosuppression have been filed in association with DAROLUTAMIDE (NUBEQA). This represents 1.4% of all adverse event reports for DAROLUTAMIDE.
44
Reports of Myelosuppression with DAROLUTAMIDE
1.4%
of all DAROLUTAMIDE reports
0
Deaths
13
Hospitalizations
How Dangerous Is Myelosuppression From DAROLUTAMIDE?
Of the 44 reports, 13 (29.5%) required hospitalization.
Is Myelosuppression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DAROLUTAMIDE. However, 44 reports have been filed with the FAERS database.
What Other Side Effects Does DAROLUTAMIDE Cause?
Fatigue (384)
Death (361)
Hot flush (203)
Asthenia (173)
Prostatic specific antigen increased (156)
Off label use (133)
Neuropathy peripheral (127)
Diarrhoea (122)
Dizziness (122)
Rash (116)
What Other Drugs Cause Myelosuppression?
CYCLOPHOSPHAMIDE (3,603)
CARBOPLATIN (2,624)
TRASTUZUMAB (2,552)
PACLITAXEL (2,522)
TISLELIZUMAB (2,142)
CYTARABINE (1,869)
VENETOCLAX (1,864)
CISPLATIN (1,849)
BEVACIZUMAB (1,744)
SODIUM (1,696)
Which DAROLUTAMIDE Alternatives Have Lower Myelosuppression Risk?
DAROLUTAMIDE vs DARUNAVIR
DAROLUTAMIDE vs DARUNAVIR ETHANOLATE
DAROLUTAMIDE vs DARUNAVIR\RITONAVIR
DAROLUTAMIDE vs DASABUVIR
DAROLUTAMIDE vs DASABUVIR\OMBITASVIR HEMINONAHYDRATE\PARITAPREVIR\RITONAVIR